Fabimycin Production Cost Reports

The report provides detailed analysis essential for establishing a fabimycin production plant. It encompasses all critical aspects necessary for fabimycin production, including the cost of fabimycin production, fabimycin plant cost, fabimycin production costs, and the overall fabimycin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a fabimycin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fabimycin Market Analysis: Demand and Supply Analysis, and Sourcing

Fabimycin is a synthetic FabI inhibitor developed as a potential antibiotic against difficult Gram-negative pathogens. It shows activity against more than 200 clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, along with efficacy in mouse infection models. The compound targets enoyl-acyl carrier protein reductase, an enzyme required for bacterial fatty-acid synthesis. Its positively charged amine helps the molecule accumulate inside Gram-negative bacteria, where the outer membrane and efflux systems block many other candidates. Fabimycin remains an investigational compound and is not an approved medicine. Its current demand is limited to antibacterial research, medicinal chemistry, pharmacology, analytical work, and pre-clinical development.

Commercial sourcing of Fabimycin is mainly limited to milligram quantities or custom synthesis orders rather than regular pharmaceutical-scale supply. Research chemical suppliers list Fabimycin under CAS number 2651965-71-6 and generally provide it only for laboratory use. Larger-scale production would generally require a fine-chemical or pharmaceutical contract manufacturer with capabilities in chiral synthesis & palladium-catalyzed coupling, handling hazardous reagents, and strict impurity control. Buyers should verify the salt form, stereochemical purity, assay, residual solvents, elemental impurities, water content & analytical data. Patent availability should also be considered, as optimized synthesis routes and FabI inhibitor applications are protected through patent filings.

Summary of the Product, Grades, and Uses

Fabimycin is the S-enantiomer of a ring-expanded naphthyridinone FabI inhibitor and is commonly represented as its hydrochloride salt. The molecular formula of the compound is C23H25ClN4O3, and the molecular weight is approximately 440.92 g/mol. The structure contains a benzofuran group, an E-configured N-methyl acrylamide linkage & a fused lactam system, and a primary amine. The amine is important for bacterial accumulation, while the stereochemical configuration supports strong target binding. Available material is generally research grade or custom synthesized. Product release tests should cover identity, assay, related substances, chiral purity, residual solvents, water, palladium & other elemental impurities, counter-ion content, and stability under the intended storage condition.

Fabimycin is primarily used in pre-clinical antibiotic research on multidrug-resistant Gram-negative bacteria. It is also used in the study of FabI inhibition, bacterial membrane permeation, efflux, resistance selection, and the relationship between intracellular accumulation & antibacterial activity. Fabimycin provides a benchmark for medicinal chemistry teams developing new FabI inhibitors or comparing analogs with different ring sizes and amine positions. Pharmacology groups require small lots for formulation & tolerability, pharmacokinetic, tissue-distribution, and infection-model studies. Analytical laboratories may use qualified material for method development, impurity tracking, or as a reference. No recognized human dosage form or licensed commercial grade has been reported.

Major End-Uses of Fabimycin

Antibacterial drug discovery is the largest current use. Researchers test Fabimycin against reference strains & resistant clinical isolates, with special attention to E. coli, K. pneumoniae, and A. baumannii. The compound has also shown strong activity against Staphylococcus aureus in laboratory studies. Its narrow effect on many commensal organisms makes it useful for work on pathogen-selective antibiotics. Buyers in this segment need highly pure, enantiomerically controlled material because small differences in stereochemistry can sharply change FabI inhibition and antibacterial potency. Consistent salt form and solution behavior are also important when comparing minimum inhibitory concentration data across laboratories.

The second application area is mechanism and resistance research. Fabimycin is used in enzyme assays, whole-cell studies, membrane models, resistant mutant studies, crystallography, and structure-activity research. The major synthesis route produced gram-scale enantiopure material for in vivo studies, after early work depended on preparative chiral separation. This makes Fabimycin useful for process chemists studying the practical production of chiral FabI inhibitors. The synthesis route also provides a case study for methods such as dynamic kinetic resolution, Beckmann ring expansion, selective halogenation, azide chemistry, Staudinger reduction, amine protection, and Heck coupling in medicinal chemistry.

A smaller application area includes custom synthesis, analytical standards, and preclinical formulation support. Research suppliers may provide packaged powder, while contract laboratories can produce batches according to customer specifications. Formulation teams use the material for solubility testing, cyclodextrin or surfactant systems, sterile preparation studies, and animal dosing studies. Analytical teams require well-characterized reference samples for HPLC, LC-MS, NMR, chiral chromatography, and impurity analysis. These applications require very small quantities compared with commercial antibiotics. Production planning should focus on flexible batch sizes, quick analytical approval & proper documentation, and the ability to adjust the process based on development results.

Fabimycin Market Risks

The main market risk is related to development uncertainty. Fabimycin has shown promising preclinical results, but current evidence is mainly based on laboratory & animal studies rather than an approved clinical program. Further studies on toxicity, formulation, pharmacokinetics, dosage, resistance, and human safety are required before commercial use. Changes in development plans could reduce demand for dedicated intermediates or research material. Patent restrictions may also affect production and supply activities. Producers should review freedom to operate, research permissions, licensing conditions, ownership of process improvements, and confidentiality requirements before starting dedicated production.

Production risk is also high because the production route involves many chemical operations and several sensitive intermediates. Yield loss can occur during oxime formation, Beckmann rearrangement, aromatic bromination & alpha-iodination, azide substitution, reduction, dynamic kinetic resolution, protection, palladium-catalyzed coupling, deprotection, and final isolation. The chiral step is especially important because the less active enantiomer must be controlled. Chemicals such as bromine, mesyl chloride, azide reagents, phosphines, strong acids, and palladium catalysts require careful handling. Residual metals, halogenated by-products, genotoxic impurities, and traces of protecting groups can increase analytical requirements. Small batch production can further raise labor, cleaning, quality control, and documentation costs per gram.

Fabimycin Production Process & Main Cost Drivers

The Fabimycin production plant report assesses the overall chemical synthesis chain and explains the cost of intermediate preparation and ring expansion. It also covers halogenation, amine installation, chiral enrichment, protection, carbon-carbon coupling, deprotection, purification, testing, and packing costs.

• By Multistep Chemical Synthesis Using Ring Expansion, Dynamic Kinetic Resolution, and Heck Coupling: The main inputs include a substituted quinolone precursor, hydroxylamine, mesyl chloride, bromine, an iodinating reagent, an azide source, a phosphine reducing reagent, and 2-hydroxy-5-nitrobenzaldehyde. They also include L-pyroglutamic acid, an amine-protecting reagent, a benzofuran-containing acrylic amide intermediate, a palladium catalyst, bases, acids, process solvents, chromatography media, and packaging materials.

Production begins with conversion of a substituted quinolone to an oxime using hydroxylamine. The oxime is activated with mesyl chloride and rearranged through a Beckmann reaction to form the seven-membered azepine lactam. Controlled bromination introduces the aryl bromide needed for the later coupling step. Alpha-iodination creates a second leaving group, which is displaced by azide and then reduced under Staudinger conditions to give the key amine. The racemic amine is enriched through a dynamic kinetic resolution that uses a temporary imine & crystallization with L-pyroglutamic acid. After release and protection of the selected amine, the brominated intermediate undergoes Heck coupling with the benzofuran acrylamide fragment. Acidic deprotection liberates Fabimycin, which is purified and isolated in the required salt form. Overall yield, chiral recovery, catalyst loading, purification burden, solvent use, and final specification drive the unit cost.

Main Factors Affecting Fabimycin Production Cost

The number of synthetic steps is the largest structural cost driver. Every stage adds raw materials, solvent, equipment time, in-process testing, isolation loss, and waste. A modest yield reduction in an early intermediate is carried through the rest of the route and raises the cost of the final gram. Specialty starting materials & the benzofuran acrylamide coupling partner may need custom preparation. Palladium catalyst, chiral resolving agents, chromatography media, dry solvents, and high-purity reagents add further expense. The dynamic kinetic resolution must deliver reliable enantiomeric purity without discarding excessive material. If the resolution is inconsistent, repeated crystallization or preparative chiral chromatography can become one of the most expensive operations.

The product grade has a strong impact on the industrial production economics. Discovery grade materials may only need to be tested for identity and purity. Toxicology or clinical grade materials must be manufactured under controlled conditions with qualified raw materials, validated analytical methods, impurity studies, cleaning records, stability data, and complete batch traceability. The process also requires extra costs for containment systems, ventilation, inert atmosphere, reaction safety studies, metal removal, and hazardous waste management. Labor and overhead costs are affected by the size of the campaign. The cost of small-scale milligram production is very high per gram. Early scale-up is expensive until the process is optimized. Patent licensing, technology transfer, analytical standards, and customer audits can add to total costs.

Raw Materials for Fabimycin Production Plant and its Procurement

The main raw material chain begins with a substituted quinolone or a suitable precursor used to develop the naphthyridinone core. Hydroxylamine and mesyl chloride are used for oxime formation & activation, followed by reagents for Beckmann ring expansion. Bromine is used for aromatic bromination, while an iodinating system introduces the alpha-iodo group. Sodium azide or another controlled azide source adds the nitrogen functionality, and a phosphine reagent converts the azide into the amine. The chiral enrichment step uses 2-hydroxy-5-nitrobenzaldehyde and L-pyroglutamic acid. A Boc-type protecting reagent is then applied before palladium-catalyzed Heck coupling with the benzofuran-containing acrylic amide intermediate.

Material quality has a direct effect on impurity formation & batch recovery. Reactive solvents can lower activation efficiency with water, and metal contamination can interfere with the coupling step or complicate elemental-impurity control. The strength specifications for bromination & iodination reagents are tight, as excess reagent can lead to increased over-halogenated by-products. Conversion and safety are a function of azide quality, phosphine purity, and temperature of reaction. L-pyroglutamic acid quality impacts salt formation and chiral enrichment. The acrylic amide partner should have controlled E geometry, purity, and storage stability. Supplier documentation and incoming testing should cover identity, activity, ligand quality, and residual metal removal of the Pd catalyst.

Purchase contracts should include chemical identity, assay, water content, impurity profile, residual solvents, packaging & shelf life, transport requirements, and change-notification procedures. Ideally, critical intermediates can be sourced from multiple qualified suppliers, but availability is sometimes limited by patents. Hazardous materials must be transported in approved containers and stored under the right conditions, including temperature controls. Custom intermediates should be procured according to actual demand, as long storage periods can affect stability and increase inventory costs. Pilot producers must have reserve samples, reference standards, and analytical equipment available before production begins. Lead times for suppliers may be longer than the reaction times, in particular for chiral intermediates & custom benzofuran fragments, and high-purity palladium catalysts.

Sustainability & Regulatory Requirements

Fabimycin synthesis can generate halogenated solvent waste, aqueous salt streams, bromine- and iodine-containing residues, spent palladium, phosphine oxide, azide-bearing waste, and mother liquors from chiral resolution. Process development should reduce solvent volumes, replace chromatography with crystallization where practical, recover reusable solvents, and improve telescoping between compatible steps. Palladium recovery can lower disposal cost and reduce metal demand. Azide reactions need concentration limits, compatible equipment, dilution rules, and checks that avoid accumulation of shock-sensitive metal azides. Bromine and mesyl chloride require closed charging, local exhaust, scrubbers, and emergency control. Waste segregation is important because mixing oxidizing, reducing, acidic, and azide-containing streams can create additional hazards.

Regulatory expectations depend on the intended use. Research-use material is sold with laboratory documentation and cannot be represented as a medicine. Material for toxicology or human investigation would need progressively stronger chemistry, production, and controls information. This includes a defined synthesis, manufacturer details, reagent and solvent lists, process controls, specifications, analytical methods, stability, packaging, and batch records. GMP principles for active pharmaceutical ingredients become relevant as the program advances. Residual solvents, elemental impurities, mutagenic impurities, chiral purity, degradation products, and microbiological quality must be assessed against the route and dosage form. Patent rights, import rules, controlled hazardous-material transport, and institutional approvals must also be reviewed before supply.

CAPEX and OPEX for a Fabimycin Production Plant

Plant investment includes glass-lined or alloy reactors, controlled low-temperature systems, inert gas supply, condensers, scrubbers, pressure-rated filtration units, centrifuges, vacuum dryers, and contained powder handling equipment. Separate or controlled systems are required for azide reactions, bromine handling, palladium coupling, and strong-acid deprotection steps. The downstream section may include phase separation units, carbon treatment, metal removal systems, crystallizers, filter dryers, milling equipment, and small-batch packaging facilities. The laboratory requires HPLC, chiral HPLC, LC-MS, gas chromatography, NMR access, water analysis, residual metal testing, and stability testing equipment. Civil infrastructure includes segregated hazardous material storage, controlled laboratories, solvent handling areas, ventilation systems, fire protection, wastewater treatment, and secure document storage. The Fabimycin plant setup cost depends on production scale, containment requirements, reactor flexibility, analytical facilities, waste treatment systems, and GMP compliance. Operating expenses include starting materials, custom intermediates, catalysts, resolving agents, solvents, utilities, labor, quality control, cleaning, maintenance, waste disposal, packaging, stability testing, and licensing or technology transfer costs. The Fabimycin production cost is mainly affected by reaction yield, chiral recovery, palladium consumption, purification requirements, batch size, and final product specifications.

Plant Location and Investment Factors

A suitable site should be part of an established pharmaceutical or fine-chemical production area with access to skilled process chemists, analytical scientists, hazardous-reaction engineering, and licensed waste treatment. The site needs reliable power, chilled water, nitrogen, vacuum, clean utilities, solvent recovery, and controlled warehousing. Proximity to air cargo & specialist chemical logistics is useful because early campaigns use small quantities of high-value materials. The local regulatory system must permit storage and use of bromine, azides, flammable solvents, compressed gases, and palladium catalysts. Emergency response & firewater containment, worker exposure controls, and secure handling of patented process information are also important.

Investors should avoid a single-product plant at the current development stage. A flexible multipurpose unit can share reactors, laboratories, utilities, and quality staff across several high-value pharmaceutical intermediates. This lowers the risk created by uncertain Fabimycin demand. The process-transfer plan should first confirm reproducibility at laboratory scale, then assess reaction heat, mixing, gas release, impurity growth, filtration, drying, and solid form. Scale should increase only after the chiral step and final crystallization are dependable. The business case depends on sponsored development, licensed rights, confirmed campaign orders, and a route that can meet toxicology or clinical specifications without excessive chromatography. Working capital must include long-lead custom intermediates and extended analytical release time.

Major Fabimycin Producing Regions

No region currently leads commercial Fabimycin production because the compound is still in the research stage. The United States is the main development hub, with the discovery work, optimized gram-scale synthesis, biological studies, and patent activities linked to US universities and research institutions. Small research quantities are listed by specialty suppliers with operations & distribution networks in China and other international markets. These listings represent research supply, not an approved API industry. India, Europe, and East Asia have capable pharmaceutical CDMO sectors that could support future route development or pilot manufacture, but no dedicated commercial Fabimycin plant has been publicly identified. A Fabimycin production plant project report should therefore evaluate custom synthesis capacity, patent access, chiral process capability, hazard management, analytical support, and the sponsor's development plan rather than rely on existing regional output. The industrial production economics depend mainly on campaign size, cumulative yield, custom intermediate cost, chiral recovery, palladium control, purification, and documentation level.

Major Fabimycin Development & Research-Supply Organizations

University of Illinois System

• The university research team led the medicinal-chemistry work that identified Fabimycin and developed an optimized route for gram-scale enantiopure material.
• Its reported synthesis uses ring expansion, selective halogenation, amine installation, dynamic kinetic resolution, protection, Heck coupling, and final deprotection.
• The institution is named as a patent assignee for FabI inhibitors aimed at Gram-negative pathogens, together with collaborating research organizations.
• Its role is discovery, process development, and intellectual-property ownership rather than routine commercial supply of approved antibiotic API.

Broad Institute, Inc.

• The Broad Institute participated in the Fabimycin discovery program and is listed as a co-assignee on the related US patent application.
• Its work supported evaluation against resistant clinical isolates and helped connect chemical design with bacterial accumulation and antimicrobial performance.
• The organization contributes translational research and pathogen-testing capability rather than operating a public commercial Fabimycin production plant.
• Partnership or licensing discussions would need to address the combined patent ownership and the permitted scope of manufacture and development.

The General Hospital Corporation

• The General Hospital Corporation is listed among the assignees for the FabI inhibitor patent family associated with Fabimycin.
• Its research contribution is tied to antibacterial biology, translational assessment, and the development case for treating resistant Gram-negative infections.
• The organization does not publicly market Fabimycin as an approved active ingredient or finished medicine.
• Any clinical supply program would require sponsor-led CMC work, qualified production, regulatory filings, and rights to use the patented compounds and route.

MedChemExpress

• Lists Fabimycin as catalog number HY-151102 for research use and identifies it as a FabI inhibitor active against Gram-negative bacteria.
• Provides small research quantities or quotation-based supply rather than standard pharmaceutical bulk production.
• Its product information identifies CAS number 2651965-71-6 and limits the material to laboratory research, not patient use.
• Buyers should confirm batch assay, chiral purity, salt form, analytical documentation, packaging, and lead time before placing an order.

TargetMol

• Lists Fabimycin as catalog number T73291 and offers research quantities with quotation and lead-time information.
• Reports the hydrochloride formula C23H25ClN4O3, molecular weight of about 440.92, and CAS number 2651965-71-6.
• Also advertises custom synthesis support, which may be relevant when a research program needs a larger or specially documented batch.
• The listed product is for research use only and should not be treated as a clinical-grade or commercially approved antibiotic API.

DC Chemicals

• Lists Fabimycin under catalog number DC71937 for research use only and provides quotation-based supply.
• Publishes the compound formula, molecular weight, CAS number & chemical structure, and basic storage information for laboratory buyers.
• Its offer represents specialty research-chemical supply rather than a validated commercial production source for human drug material.
• Technical qualification should cover synthetic origin, identity, purity, stereochemistry, residual solvents, elemental impurities, and certificate-of-analysis data.